View Author
patient topotecan cancer study paclitaxel pharmacokinetic plasma cisplatin phase toxicity treatment administration level concentration grade infusion sunitinib lactone tumor combination inhibitor cremophor el effect blood cremophor dose level oncol sample clearance analysis topoisomerase topoisomerase i inhibitors course agent verweij j table schedule cycle polymorphism phase i study topotecan lactone phase i therapy ratio verweij exposure result chapter dosing sparreboom sequence desmoid neutropenia disposition activity diflomotecan range value telatinib parameter response chemotherapy bioavailability formulation group variability pharmacodynamic interaction regimen 5 days factor 1998. ifosfamide 3 weeks function camptothecin taxol gelderblom vehicle kinase
10 Most Recent Publications
|
Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib
(Article)
Veldt, A.A.M. van der Eechoute, K. Gelderblom, A.J. Gietema, J.A. Guchelaar, H.J. Erp, N.P. van Eertwegh, A.J.M. van den Haanen, J.B. Mathijssen, R.H.J. Wessels, J.A.M. |
2011-02-01
|
|
Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors
(Article)
Steeghs, N. Gelderblom, A.J. Wessels, J. Eskens, F.A.L.M. Bont, N. de Nortier, J.W. Guchelaar, H.J. |
2011-02-01
|
|
Evaluation of management of desmoid tumours associated with familial adenomatous polyposis in Dutch patients
(Article)
Nieuwenhuis, M.H. Mathus-Vliegen, E.M.H. Peters, F.T. Dam , R. van Gemert, W.G. Stuifbergen, W.N.H.M. Schouten, W.R. Gelderblom, A.J. Vasen, H.F. Nagengast, F.M. Bijl, J. van der Dalsen, A.D. Kleibeuker, J.H. Baeten, C.G.M.I. Dekker, E. Langers, A.M. Vecht, C.J. |
2010-11-09
|
|
Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination
(Article)
Abdulrahman, R.M. Verloop, H. Romijn, J.A. Visser, T.J. Smit, J.W.A. Hoftijzer, H. Verburg, E. Hovens, G.C. Corssmit, E.P. Reiners, C. Gelderblom, A.J. Pereira, A.M. Kapiteijn, E. |
2010-08-01
|
|
Pharmacogenetics of tomorrow: The 1 + 1 = 3 principle
(Article)
Pander, J. Wessels, J.A.M. Mathijssen, R.H.J. Gelderblom, A.J. Guchelaar, H.J. |
2010-07-01
|
|
Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies
(Article)
Hamberg, P. Steeghs, N. Loos, W.J. Biessen, D. van de Hollander, M. den Tascilar, M. Verweij, J. Gelderblom, A.J. Sleijfer, S. |
2010-06-08
|
|
Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib
(Article)
Steeghs, N. Mathijssen, R.H.J. Guchelaar, H.J. Wessels, J.A.M. Graan, A-J.M. de Straaten, T.J. van der Mariani, M. Laffranchi, B. Comis, S. Jonge, M.J.A. de Gelderblom, A.J. |
2010-03-08
|
|
Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
(Article)
Eskens, F.A.L.M. Steeghs, N. Rajagopalan, P. Gelderblom, A.J. Verweij, J. Bloem, J.L. Christensen, O. Doorn, L. van Ouwerkerk, J. Jonge, M.J.A. de Nortier, J.W. Kraetzschmar, J. |
2009-09-01
|
|
Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors
(Article)
Gelderblom, A.J. Prunonosa, J. Obach, R. Jonge, M.J.A. de Twelves, C. Principe, P. Salazar, R. Verweij, J. Pentheroudakis, G. Devlin, M. Hooije, C. van Seguy, F. |
2003-01-01
|
|
Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel
(Article)
Gelderblom, A.J. Verweij, J. Zomeren, D.M. van Buijs, D. Ouwens, L. Nooter, K. Stoter, G. Sparreboom, A. |
2002-01-01
|
